Literature DB >> 22217451

Mood-stabilizing drugs: mechanisms of action.

Robert J Schloesser1, Keri Martinowich, Husseini K Manji.   

Abstract

Mood-stabilizing drugs are the most widely prescribed pharmacological treatments for bipolar disorder, a disease characterized by recurrent episodes of mania and depression. Despite extensive clinical utilization, significant questions concerning their mechanisms of action remain. In recent years, a diverse set of molecular and cellular targets of these drugs has been identified. Based on these findings, downstream effects on neural and synaptic plasticity within key circuits have been proposed. Here, we discuss recent data, identify current challenges impeding progress and define areas for future investigation. Further understanding of the primary targets and downstream levels of convergence of mood-stabilizing drugs will guide development of novel therapeutic strategies and help translate discoveries into more effective treatments with less burdensome adverse-effect profiles.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22217451     DOI: 10.1016/j.tins.2011.11.009

Source DB:  PubMed          Journal:  Trends Neurosci        ISSN: 0166-2236            Impact factor:   13.837


  43 in total

1.  Neuroimaging and neurocognitive abnormalities associated with bipolar disorder in old age.

Authors:  Soham Rej; Meryl A Butters; Howard J Aizenstein; Amy Begley; Jawad Tsay; Charles F Reynolds; Benoit H Mulsant; Ariel Gildengers
Journal:  Int J Geriatr Psychiatry       Date:  2013-09-05       Impact factor: 3.485

2.  Honokiol Exerts Antidepressant Effects in Rats Exposed to Chronic Unpredictable Mild Stress by Regulating Brain Derived Neurotrophic Factor Level and Hypothalamus-Pituitary-Adrenal Axis Activity.

Authors:  Canmao Wang; Danna Gan; Jingang Wu; Minhui Liao; Xinghuan Liao; Weipeng Ai
Journal:  Neurochem Res       Date:  2018-05-31       Impact factor: 3.996

3.  Metalloneurochemistry and the Pierian Spring: 'Shallow Draughts Intoxicate the Brain'.

Authors:  Jacob M Goldberg; Andrei Loas; Stephen J Lippard
Journal:  Isr J Chem       Date:  2016-07-29       Impact factor: 3.333

4.  Valproic Acid for a Treatment of Retinitis Pigmentosa: Reasons for Optimism and Caution.

Authors:  Levi Todd; Christopher Zelinka
Journal:  J Neurosci       Date:  2017-05-24       Impact factor: 6.167

5.  Longer lithium exposure is associated with better white matter integrity in older adults with bipolar disorder.

Authors:  Ariel G Gildengers; Meryl A Butters; Howard J Aizenstein; Megan M Marron; James Emanuel; Stewart J Anderson; Lisa A Weissfeld; James T Becker; Oscar L Lopez; Benoit H Mulsant; Charles F Reynolds
Journal:  Bipolar Disord       Date:  2014-09-25       Impact factor: 6.744

6.  Lithium and GSK-3β promoter gene variants influence cortical gray matter volumes in bipolar disorder.

Authors:  Francesco Benedetti; Sara Poletti; Daniele Radaelli; Clara Locatelli; Adele Pirovano; Cristina Lorenzi; Benedetta Vai; Irene Bollettini; Andrea Falini; Enrico Smeraldi; Cristina Colombo
Journal:  Psychopharmacology (Berl)       Date:  2014-10-28       Impact factor: 4.530

7.  Influence of an interaction between lithium salts and a functional polymorphism in SLC1A2 on the history of illness in bipolar disorder.

Authors:  Sara Dallaspezia; Sara Poletti; Cristina Lorenzi; Adele Pirovano; Cristina Colombo; Francesco Benedetti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

8.  Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid.

Authors:  F Calabrese; A Luoni; G Guidotti; G Racagni; F Fumagalli; M A Riva
Journal:  Psychopharmacology (Berl)       Date:  2012-10-24       Impact factor: 4.530

9.  Atrophy of pyramidal neurons and increased stress-induced glutamate levels in CA3 following chronic suppression of adult neurogenesis.

Authors:  Robert J Schloesser; Dennisse V Jimenez; Nicholas F Hardy; Daniel Paredes; Briony J Catlow; Husseini K Manji; Ronald D McKay; Keri Martinowich
Journal:  Brain Struct Funct       Date:  2013-03-13       Impact factor: 3.270

10.  SorCS2 is required for BDNF-dependent plasticity in the hippocampus.

Authors:  S Glerup; U Bolcho; S Mølgaard; S Bøggild; C B Vaegter; A H Smith; J L Nieto-Gonzalez; P L Ovesen; L F Pedersen; A N Fjorback; M Kjolby; H Login; M M Holm; O M Andersen; J R Nyengaard; T E Willnow; K Jensen; A Nykjaer
Journal:  Mol Psychiatry       Date:  2016-07-26       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.